Song, Johanna S.Tawa, MarianneChau, Nicole G.Kupper, ThomasLeboeuf, Nicole2017-04-062017Song, Johanna S., Marianne Tawa, Nicole G. Chau, Thomas S. Kupper, and Nicole R. LeBoeuf. 2017. “Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.” BMC Cancer 17 (1): 200. doi:10.1186/s12885-017-3194-8. http://dx.doi.org/10.1186/s12885-017-3194-8.http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072025Background: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. Case presentations We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following aprepitant treatment. Conclusion: Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials.en-USCutaneous T-cell lymphomaAprepitantEmendPruritusItchCase reportJournal Article2017-04-0610.1186/s12885-017-3194-8